Terms: = Lung cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Staging
171 results:
1. The radiological characteristics, tertiary lymphoid structures, and survival status associated with egfr mutation in patients with subsolid nodules like stage I-II LUAD.
Xie M; Gao J; Ma X; Song J; Wu C; Zhou Y; Jiang T; Liang Y; Yang C; Bao X; Zhang X; Yao J; Jing Y; Wu J; Wang J; Xue X
BMC Cancer; 2024 Mar; 24(1):372. PubMed ID: 38528507
[TBL] [Abstract] [Full Text] [Related]
2. Study on Targeted Drugs for Non-Small Cell NSCLC with PD-1PD-L1 Signaling Pathway.
Cao X
Stud Health Technol Inform; 2023 Nov; 308():562-567. PubMed ID: 38007784
[TBL] [Abstract] [Full Text] [Related]
3. Perioperative Durvalumab for Resectable Non-Small-Cell lung cancer.
Heymach JV; Harpole D; Mitsudomi T; Taube JM; Galffy G; Hochmair M; Winder T; Zukov R; Garbaos G; Gao S; Kuroda H; Ostoros G; Tran TV; You J; Lee KY; Antonuzzo L; Papai-Szekely Z; Akamatsu H; Biswas B; Spira A; Crawford J; Le HT; Aperghis M; Doherty GJ; Mann H; Fouad TM; Reck M;
N Engl J Med; 2023 Nov; 389(18):1672-1684. PubMed ID: 37870974
[TBL] [Abstract] [Full Text] [Related]
4. A real-world study comparing perioperative chemotherapy and egfr-tyrosine kinase inhibitors for treatment of resected stage III egfr-mutant adenocarcinoma.
Chen CL; Wang ST; Liao WC; Chen CH; Tu CY; Hsia TC; Cheng WC; Chen HJ
BMC Cancer; 2023 Sep; 23(1):847. PubMed ID: 37697233
[TBL] [Abstract] [Full Text] [Related]
5. Whole exome sequencing and MicroRNA profiling of lung adenocarcinoma identified risk prediction features for tumors at stage I and its substages.
Ho H; Yu SL; Chen HY; Yuan SS; Su KY; Hsu YC; Hsu CP; Chuang CY; Chang YH; Li YC; Cheng CL; Chang GC; Yang PC; Li KC
Lung Cancer; 2023 Oct; 184():107352. PubMed ID: 37657238
[TBL] [Abstract] [Full Text] [Related]
6. Combined large cell neuroendocrine carcinoma, lung adenocarcinoma, and squamous cell carcinoma: a case report and review of the literature.
Zhu Z; Liu Y; Xu H; Ning H; Xia Y; Shen L
J Cardiothorac Surg; 2023 Aug; 18(1):254. PubMed ID: 37653509
[TBL] [Abstract] [Full Text] [Related]
7. Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis.
Gillespie CS; Mustafa MA; Richardson GE; Alam AM; Lee KS; Hughes DM; Escriu C; Zakaria R
J Thorac Oncol; 2023 Dec; 18(12):1703-1713. PubMed ID: 37392903
[TBL] [Abstract] [Full Text] [Related]
8. Programmed Death Ligand -1 and Gene Mutation Characterization of lung Malignancies in Patients at a Rural Hospital in Central India.
Kanthali M; Mamgain P; Dhawan P; Bhagwat G; Patel S; Purohit MR
Asian Pac J Cancer Prev; 2023 Jun; 24(6):1855-1861. PubMed ID: 37378912
[TBL] [Abstract] [Full Text] [Related]
9. Clinical characteristics of miliary pulmonary metastases in non-small cell lung cancer.
Choi H; Im Y; Jeong BH; Lee K; Kim H; Um SW
Thorac Cancer; 2023 Aug; 14(22):2168-2176. PubMed ID: 37337934
[TBL] [Abstract] [Full Text] [Related]
10. [A Case of Multiple Brain Metastases after Surgery for lung cancer Successfully Treated with Osimertinib].
Takeuchi K; Hayakawa N; Ouchi M
Gan To Kagaku Ryoho; 2023 May; 50(5):631-633. PubMed ID: 37218327
[TBL] [Abstract] [Full Text] [Related]
11. Distribution and prognostic impact of egfr and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma.
Ito M; Miyata Y; Kushitani K; Ueda D; Takeshima Y; Okada M
BMC Cancer; 2023 Mar; 23(1):248. PubMed ID: 36918771
[TBL] [Abstract] [Full Text] [Related]
12. Different prognostic role of egfr mutation according to the IASLC histological grade in patients with resected early-stage lung adenocarcinoma.
Hong TH; Hwang S; Choi YL; Lee G; Park S; Ahn MJ; Lee Y; Jeon YJ; Lee J; Shin S; Park SY; Cho JH; Choi YS; Kim J; Shim YM; Cho J; Kim HK
Histopathology; 2023 Aug; 83(2):168-177. PubMed ID: 36849852
[TBL] [Abstract] [Full Text] [Related]
13. [Gefitinib Monotherapy Afforded Long-Term Survival of an Octogenarian Patient with a Postoperative Recurrence of a Pulmonary Adenocarcinoma-A Case Report].
Kamiyoshihara M; Igai H; Ohsawa F; Numajiri K
Gan To Kagaku Ryoho; 2023 Feb; 50(2):187-189. PubMed ID: 36807168
[TBL] [Abstract] [Full Text] [Related]
14. The role of brain radiotherapy for egfr- and ALK-positive non-small-cell lung cancer with brain metastases: a review.
Nardone V; Romeo C; D'Ippolito E; Pastina P; D'Apolito M; Pirtoli L; Caraglia M; Mutti L; Bianco G; Falzea AC; Giannicola R; Giordano A; Tagliaferri P; Vinciguerra C; Desideri I; Loi M; Reginelli A; Cappabianca S; Tassone P; Correale P
Radiol Med; 2023 Mar; 128(3):316-329. PubMed ID: 36786970
[TBL] [Abstract] [Full Text] [Related]
15. Genetic Associations of
Chang SL; Yang PJ; Lin YY; Jiang YJ; Liu PI; Huang CL; Yang SF; Tang CH
Int J Environ Res Public Health; 2022 Nov; 19(22):. PubMed ID: 36429891
[TBL] [Abstract] [Full Text] [Related]
16. LINC02126 is a potential diagnostic, prognostic and immunotherapeutic target for lung adenocarcinoma.
Wang J; Liu J; Hou Q; Xu M
BMC Pulm Med; 2022 Nov; 22(1):412. PubMed ID: 36357869
[TBL] [Abstract] [Full Text] [Related]
17. A novel egfr exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report.
Zhou T; Xiong Q; Hong C; Wang Q; Wang W; Xu C; Cai J;
Medicine (Baltimore); 2022 Aug; 101(34):e30269. PubMed ID: 36042660
[TBL] [Abstract] [Full Text] [Related]
18. Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries.
Soo R; Mery L; Bardot A; Kanesvaran R; Keong TC; Pongnikorn D; Prasongsook N; Hutajulu SH; Irawan C; Manan AA; Thiagarajan M; Sripan P; Peters S; Storm H; Bray F; Stahel R
ESMO Open; 2022 Oct; 7(5):100560. PubMed ID: 35988454
[TBL] [Abstract] [Full Text] [Related]
19. IMPORTANCE of PRETREATMENT 18F-FDG PET/CT TEXTURE ANALYSIS in PREDICTING egfr and ALK MUTATION in PATIENTS with NON-SMALL CELL lung cancer.
Agüloğlu N; Aksu A; Akyol M; Katgı N; Doksöz TÇ
Nuklearmedizin; 2022 Dec; 61(6):433-439. PubMed ID: 35977671
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic outcome of treatment modalities for epidermal growth factor receptor-mutated advanced lung cancer.
Jang SH; Lee DY; Jeong J; Choi WI
Korean J Intern Med; 2022 Jul; 37(4):811-820. PubMed ID: 35811369
[TBL] [Abstract] [Full Text] [Related]
[Next]
